Results 1 to 10 of about 4,101 (195)

Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication [PDF]

Journal for ImmunoTherapy of Cancer, 2020
Background Oncolytic therapy uses live-replicating viruses to improve the immunological status of treated tumors. Critically, while these viruses are known to self-amplify in vivo, clinical oncolytic therapies still appear to display a strong dose ...
Eric Bartee, Erica B Flores, Bulent A Aksoy   +2 more
doaj   +3 more sources

Recombinant Myxoma Virus in European Brown Hares, 2023–2024 [PDF]

Emerging Infectious Diseases
Recombinant myxoma virus has emerged in European brown hares (Lepus europaeus), causing increased deaths associated with swollen eyelids, head edema, and dermatitis at face, legs, and perineum. Introduction may date back as far as September 2020.
Luisa Fischer, Erwin de Bruin, Evelien Jongepier, Erik Koffeman, Patricia König, Florian Pfaff, Martin Peters, Judith M.A. van den Brand, Marin Bussi, Dominik Fischer, Valentina Caliendo, Erik Weerts, Jooske IJzer, Janina Müller, Ann-Katrin Kühling, Maren Kummerfeld, Jana Müller, Henning Petersen, Sabine Merbach, Martin Beer, Mathilde Uiterwijk, Karst de Boer, Jolianne M. Rijks   +22 more
doaj   +3 more sources

Effect of Myxoma Virus Species Jump on Iberian Hare Populations [PDF]

Emerging Infectious Diseases
The myxoma virus species jump from European rabbits (Oryctolagus cuniculus) to Iberian hares (Lepus granatensis) has raised concerns. We assess the decline suffered by Iberian hare populations on the Iberian Peninsula and discuss the association between
Beatriz Cardoso, Ignacio García-Bocanegra, João Queirós, Javier Fernández-López, Paulo C. Alves, Pelayo Acevedo   +5 more
doaj   +3 more sources

Myxoma Virus-Loaded Mesenchymal Stem Cells in Experimental Oncolytic Therapy of Murine Pulmonary Melanoma [PDF]

Molecular Therapy: Oncolytics, 2020
Oncolytic viruses can target neoplasms, triggering oncolytic and immune effects. Their delivery to melanoma lesions remains challenging. Bone-marrow-derived mesenchymal stem cells (MSCs) were shown to be permissive for oncolytic myxoma virus (MYXV ...
Joanna Jazowiecka-Rakus, Aleksander Sochanik, Aleksandra Rusin, Agata Hadryś, Wojciech Fidyk, Nancy Villa, Masmudur M. Rahman, Ewa Chmielik, Lina S. Franco, Grant McFadden   +9 more
doaj   +4 more sources

Systemic delivery of TNF-armed myxoma virus plus immune checkpoint inhibitor eliminates lung metastatic mouse osteosarcoma [PDF]

Molecular Therapy: Oncolytics, 2021
Solid cancers that metastasize to the lungs represent a major therapeutic challenge. Current treatment paradigms for lung metastases consist of radiation therapy, chemotherapies, and surgical resection, but there is no single treatment or combination ...
John D. Christie, Nicole Appel, Hannah Canter, Jazmin Galvan Achi, Natalie M. Elliott, Ana Lemos de Matos, Lina Franco, Jacquelyn Kilbourne, Kenneth Lowe, Masmudur M. Rahman, Nancy Y. Villa, Joshua Carmen, Evelyn Luna, Joseph Blattman, Grant McFadden   +14 more
doaj   +4 more sources

Evaluation of Commercial Myxomatosis Vaccines against Recombinant Myxoma Virus (ha-MYXV) in Iberian Hare and Wild Rabbit [PDF]

Vaccines, 2022
The recent emergence of a new myxoma virus capable of causing disease in the Iberian hare (Lepus granatensis) has resulted in numerous outbreaks with high mortality leading to the reduction, or even the disappearance, of many local populations of this ...
Fábio A. Abade dos Santos, Carina L. Carvalho, Pâmela C. L. G. Valente, Henrique Armés, Sylvia S. Reemers, Maria C. Peleteiro, Inés Calonge Sanz, Kevin P. Dalton, Francisco Parra, Margarida D. Duarte   +9 more
doaj   +2 more sources

Emergence of Recombinant Myxoma Virus in Algerian Farmed Rabbits: Molecular and Phylogenetic Evidence. [PDF]

Transbound Emerg Dis
Myxomatosis is a severe viral disease of lagomorphs that has recently seen the emergence of a recombinant myxoma virus (MYXV). Data from Africa remain scarce. Here we report the first confirmed detection and genomic characterization of a recombinant MYXV in Algeria.
Maziz-Bettahar S, Montacq L, Caubet C, Gaide N, Yahouni-Slimani F, Sahraoui L, Bertagnoli S.   +6 more
europepmc   +2 more sources

Enrichment and Reduction of Microsatellite Regions in the Myxoma Virus Genome Following Species Jump to the Iberian Hare (<i>Lepus granatensis</i>). [PDF]

Transbound Emerg Dis
Myxoma virus (MYXV), the causative agent of myxomatosis, is endemic in wild populations of the European rabbit (Oryctolagus cuniculus). In 2018, the virus acquired four genes (M157L, M158L, M159L and M160L) from a yet unidentified source and gained the capacity to infect the Iberian hare (Lepus granatensis).
Menéndez-Manjón A, Cardoso B, Castro-Scholten S, Agüero M, Duran M, Buitrago D, Lopes AM, Abrantes J, Martinez-Haro M, Cano-Terriza D, Jiménez-Martín D, Camacho-Sillero L, Nicieza I, Arenas-Vicente S, Calonge-Sanz I, Parra F, Alvarez AL, Domínguez P, Martín-Alonso JM, García-Bocanegra I, Dalton KP.   +20 more
europepmc   +2 more sources

The Role of Myxoma Virus Immune Modulators and Host Range Factors in Pathogenesis and Species Leaping [PDF]

Viruses
Myxoma virus (MYXV) is a leporipoxvirus that causes lethal disease in Leporids. Hares and rabbits belong to the Leporidae family and are believed to have had a common ancestor 12 million years ago.
Junior A. Enow, Ana M. Lopes, Joana Abrantes, Pedro J. Esteves, Masmudur M. Rahman   +4 more
doaj   +2 more sources

Decreasing the Susceptibility of Malignant Cells to Infection Does Not Impact the Overall Efficacy of Myxoma Virus-Based Oncolytic Virotherapy [PDF]

Molecular Therapy: Oncolytics, 2020
Oncolytic virotherapy relies on the induction of anti-tumor immune responses to achieve therapeutic efficacy. The factors that influence the induction of these responses, however, are not well understood.
Erica B. Flores, Eric Bartee
doaj   +2 more sources